Karuna Therapeutics Inc. (KRTX) Confirms Proposed 2.6M Share Public Offering of Common Stock

Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that it has commenced an underwritten public offering of 2,600,000 shares of its common stock. Karuna intends to grant the underwriters a 30-day option to purchase an additional 390,000 shares of its common stock, at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size and terms of the offering. All the shares to be sold in the proposed offering will be sold by Karuna.

Goldman Sachs & Co. LLC and Citigroup are acting as joint book-running managers for the offering. Stifel, Nicolaus & Company, Incorporated is also acting as a book-running manager. JMP Securities LLC is acting as a lead manager.

A registration statement relating to these securities was filed with the Securities and Exchange Commission ("SEC") on November 18, 2019 but has not yet been declared effective.

You May Also Be Interested In

• Ambiq launches public offering of 1.8 million shares
• AMTD group discloses share repurchase totals, plans to expand buybacks
• FDA backs Entera Bio's Phase 3 trial plan for oral osteoporosis drug